Inositol pyrophosphates such as 5-diphosphoinositol pentakisphosphate (5-IP 7 ) are highly energetic inositol metabolites containing phosphoanhydride bonds. Although inositol pyrophosphates are known to regulate various biological events, including growth, survival, and metabolism, the molecular sites of 5-IP 7 action in vesicle trafficking have remained largely elusive. We report here that elevated 5-IP 7 levels, caused by overexpression of inositol hexakisphosphate (IP 6 ) kinase 1 (IP6K1), suppressed depolarization-induced neurotransmitter release from PC12 cells. Conversely, IP6K1 depletion decreased intracellular 5-IP 7 concentrations, leading to increased neurotransmitter release. Consistently, knockdown of IP6K1 in cultured hippocampal neurons augmented action potential-driven synaptic vesicle exocytosis at synapses. Using a FRET-based in vitro vesicle fusion assay, we found that 5-IP 7 , but not 1-IP 7 , exhibited significantly higher inhibitory activity toward synaptic vesicle exocytosis than IP 6 . Synaptotagmin 1 (Syt1), a Ca 2+ sensor essential for synaptic membrane fusion, was identified as a molecular target of 5-IP 7 . Notably, 5-IP 7 showed a 45-fold higher binding affinity for Syt1 compared with IP 6 . In addition, 5-IP 7 -dependent inhibition of synaptic vesicle fusion was abolished by increasing Ca 2+ levels. Thus, 5-IP 7 appears to act through Syt1 binding to interfere with the fusogenic activity of Ca
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inositol pyrophosphate | synaptotagmin | synaptic vesicle exocytosis I nositol phosphates (IPs) exist in all types of organisms from yeast to mammals. Inositol 1,4,5-trisphosphate (IP 3 ) is a well-known second messenger that elevates cytosolic Ca 2+ levels through direct binding and activation of IP 3 -gated Ca 2+ channels (1) . Recently, inositol pyrophosphates with highly energetic pyrophosphate bonds have been reported (2) . In mammals, the most extensively characterized inositol pyrophosphate is 5-diphosphoinositol pentakisphosphate (5-PP-[1,2,3,4,6]IP 5 ), designated 5-IP 7 . The 5-IP 7 is synthesized by phosphorylation at position 5 of the fully phosphorylated six-carbon inositol, inositol hexakisphosphate (IP 6 ) (3). Another IP 7 isomer, 1/3-PP-IP 5 (1-IP 7 ), influences phosphate homeostasis in yeast by binding to the cyclin/cyclin-dependent kinase complex and inactivating its function (3) (4) (5) . The significant role of IP 7 in coordinating growth and metabolism of mammalian cells has been highlighted (6, 7) . Mechanistically, IP 7 appears to signal through either covalent modification of proteins through phosphotransfer reactions (8) or allosteric interactions with specific receptor proteins (6) . With few exceptions, such as Akt/PKB, which is inhibited when bound to 5-IP 7 (6, 9) , the proteins that are directly targeted by IP 7 and the mechanism by which IP 7 allosterically modulates target protein function remain largely unknown.
Exocytosis is a key form of cell-cell communication, as represented by neurotransmitter release. This fundamental process is orchestrated by a group of proteins that includes soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) and synaptotagmin (Syt) (10) (11) (12) (13) (14) (15) . Once influx of Ca 2+ occurs at the presynaptic terminal, Ca 2+ -bound Syt1 governs vesicle fusion through macromolecular interactions with lipid membranes as well as SNARE proteins (11, (13) (14) (15) . Since the early 1990s, IPs have been recognized as Syt-binding metabolites that down-regulate synaptic exocytosis, but their weak binding affinities for Syt and a lack of mechanistic understanding have cast doubt on their physiological relevance (16) (17) (18) (19) . Recently, IP 6 was also shown to suppress excitatory neurotransmission by inhibiting the presynaptic Syt1-C2B domain (20) . In contrast, a study by Luo et al. proposed that IP 6 kinase 1 (IP6K1), which is responsible for 5-IP 7 synthesis, promotes synaptic vesicle exocytosis in a 5-IP 7 -independent manner through direct protein-protein interactions between IP6K1 and guanine nucleotide exchange factor for Rab3A (GRAB) (21) .
Given the unique chemical configuration of the IP 7 structure, the dynamic turnover of cellular IP 7 levels (9, (22) (23) (24) (25) , and implications
Significance
Inositol phosphates have long been considered to be negative regulators of synaptic exocytosis, but the function of diphosphoinositol pentakisphosphate (IP 7 ) has remained elusive. We found that overexpression and depletion of inositol hexakisphosphate (IP 6 ) kinase in PC12 cells or hippocampal neurons led to a reduction and increase in neurotransmitter release, respectively. Biophysical assays revealed that 5-IP 7 inhibited Ca 2+ -induced synaptic membrane fusion at a concentration one order of magnitude lower than that required for IP 6 . We further elucidated the molecular mechanism responsible for 5-IP 7 actions, demonstrating that 5-IP 7 directly bound with high affinity to synaptotagmin 1 (Syt1), a Ca 2+ sensor in cellular exocytosis, and suppressed its fusogenic activity. Thus, our data propose 5-IP 7 as a potent inhibitor of Syt1 actions on Ca
2+
-mediated synaptic vesicle fusion. of its function in vesicular trafficking (26, 27) , we investigated the possible role of 5-IP 7 in the regulation of synaptic vesicle exocytosis at the cell and single-molecule level. Here, we report that increasing 5-IP 7 levels in PC12 cells by overexpressing IP6K1 inhibited neurotransmitter release, whereas decreasing 5-IP 7 levels by small interfering RNA (siRNA)-mediated IP6K1 knockdown stimulated neurotransmitter release. Consistently, short-hairpin RNA (shRNA)-mediated knockdown of IP6K1 in cultured hippocampal neurons augmented action potential (AP)-driven synaptic vesicle exocytosis at synapses, suggesting that 5-IP 7 is a physiologic inhibitor of synaptic vesicle exocytosis. FRET-based biophysical analyses of reconstituted synaptic vesicles further revealed that 5-IP 7 is significantly more potent in suppressing synaptic membrane fusion than other IPs, such as IP 6 and 1-IP 7 . We identified Syt1 as the molecular target of 5-IP 7 actions, showing that 5-IP 7 binds to Syt1 with an affinity more than one order of magnitude higher than that of IP 6 . Our present study therefore defines 5-IP 7 as a negative regulator that potently inhibits Syt1 and ultimately suppresses Ca 2+ -evoked synaptic exocytosis.
Results
The 5-IP 7 Suppresses Neurotransmitter Release in PC12 Cells. To determine the physiological effects of 5-IP 7 in synaptic exocytosis, we first examined noradrenaline release by PC12 cells. PC12 cells, which use SNARE and Syt1 proteins for release of synaptic vesicles and large dense-core granules (28) , were loaded with radioactive (21) . To understand these apparently discrepant results, we depleted IP6K1 in PC12 cells using a specific siRNA. This siRNA treatment resulted in a >90% reduction in endogenous IP6K1 protein levels, which in turn led to a ∼67% decrease in cellular IP 7 levels (Figs. S1 D and E and S3). Under IP6K1-depleted conditions, neurotransmitter release was significantly increased (2.5-fold) compared with control cells treated with scrambled siRNA (Fig. S1F) . Our results strongly suggest that 5-IP 7 acts to suppress synaptic vesicle exocytosis in PC12 cells.
Depletion of IP6K1 Potentiates Activity-Driven Synaptic Vesicle Exocytosis in Primary Hippocampal Neurons. To further verify whether depletion of IP6K1 affects synaptic vesicle release at central nervous system (CNS) synapses, we examined activity-driven exocytosis in rat primary cultured hippocampal neurons using a vGlut1-pHluorin (vGlut1-pH)-based assay combined with shRNA targeting IP6K1. When combined with a wide-field optical imaging system, this vGlut1-pH-based assay, in which the pHluorin label shows increased fluorescence upon deacidification of the vesicle lumen, has been used to monitor synaptic vesicle exocytosis at CNS synapses (30) (31) (32) (33) . We monitored vGlut1-pH responses of hippocampal neurons to 100 AP stimuli at 10 Hz, equivalent to the simultaneous monitoring of approximately 30-40 boutons of an individual neuron, in the presence or absence of shRNA against IP6K1 (sh-IP6K1). Increase in pHluorin fluorescence, which correlated with the amount of vesicle exocytosis, was measured at each synaptic bouton. We also assessed the maximum increase in pHluorin fluorescence at the corresponding bouton by stimulating its entire vesicle pool with NH 4 Cl. Normalized fluorescence change (normalized ΔF) was calculated by dividing the observed fluorescence change by the maximum change observed in response to alkalization.
Normalized ΔF was significantly higher in sh-IP6K1-transfected neurons (0.32 ± 0.03) than in control neurons (0.21 ± 0.02) (Fig. 1  A-C and Fig. S4) . Measurements of the level of expression of IP6K1 in individual neurons after live cell imaging showed that endogenous IP6K1 protein levels were significantly lower by ∼70% in sh-IP6K1-transfected neurons than in control neurons ( Fig. 1 D and E) . Collectively, these results show that synaptic vesicle exocytosis in the IP6K1-depleted hippocampal neurons was potentiated by ∼50%, suggesting that 5-IP 7 acts in a physiological setting to suppress synaptic vesicle exocytosis at CNS synapses. To dissect the effect of 5-IP 7 in the regulation of synaptic vesicle exocytosis, we used an in vitro vesicle fusion system that allowed monitoring of SNARE-and Syt1-mediated membrane fusion down to the single-vesicle level (34) (35) (36) (37) (38) (39) (40) (41) (Fig. 2) . In this vesicle-vesicle fusion assay, one group of vesicles (v vesicles) was reconstituted with vesicle associated membrane protein 2 (vamp2; v-SNAREs) and Syt1. The other group of vesicles (t vesicles) was reconstituted with a precomplex of t-SNARE proteins [syntaxin 1 HT and synaptosomal-associated protein 25 (SNAP-25)] stabilized by the C-terminal fragment of vamp2 (42) (Fig. S5 ). This set of SNARE and Syt proteins has been shown to be responsible for synaptic vesicle exocytosis in hippocampal neurons (11, 15) and PC12 cells (43) . We previously reported that the fusogenic activity of membrane-anchored Syt1 can be recapitulated in vitro by providing a charge imbalance to v-and t-vesicle membranes (39) . Specifically, we used 3 mol percent (mol%) phosphatidylserine (PS) lipids for the v-vesicle membrane, while adding 15 mol% PS and 1 mol% phosphatidylinositol 4,5-bisphosphate (PIP 2 ) for the t vesicle. Moreover, we included 1 mM Mg 2+ ions and 1 mM ATP in the fusion reaction buffer to mimic the physiological concentrations of divalent ions and multivalent pyrophosphate molecules (41, 44) . Under these conditions, fusion kinetics, measured by the mixing of lipid dyes that constitute a FRET donor and acceptor pair [1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate (DiD)], was significantly accelerated at a Ca 2+ concentration of 100 μM (Fig. S6) . Because this Ca
2+
-evoked acceleration of vesicle-vesicle fusion was observed in a bulk assay setting, we reasoned that a majority of vesicle-vesicle fusion events, rather than that of a small subset of vesicles, was accelerated.
Addition of IP 6 or IP 7 to the fusion reaction buffer caused a marked inhibition of SNARE-and Syt1-mediated membrane fusion ( Fig. 2 A and B) . Remarkably, 5-IP 7 was 10-fold more potent in inhibiting membrane fusion than IP 6 (Fig. 2C) . As a measure of fusion activity, we compared fluorescence changes at 5 min after initiation of fusion by mixing of t and v vesicles. Whereas 429 μM IP 6 was needed to decrease the fusion activity by 50% (i.e., IC 50 value), 44 μM 5-IP 7 was sufficient to achieve the same level of suppression (Fig. 2C) . Similar potent inhibition was not detected with 1-IP 7 or other IPs [e.g., inositol 1,3,4,5-tetrakisphosphate (IP 4 ) or inositol 1,3,4,5,6-pentakisphosphate (IP 5 )], indicating the specificity of the 5-IP 7 effect (Fig. 2C and Fig. S7) .
We further examined the inhibitory effect of 5-IP 7 on fusion at the single-vesicle level. Single vesicle-vesicle docking kinetics were monitored by immobilizing 30,000 v vesicles in an imaging area of 45 × 90 μm 2 and reacting them with 0.1 μM t vesicles (Fig. S8) . After reacting for 30 s, the single-vesicle docking number (i.e., number of docked t vesicles for each imaging area), which we assumed was proportional to the kinetic rate of docking between v and t vesicles, was quantified. The addition of 5-IP 7 led to a significant reduction in the single-vesicle docking number, an effect that was evident at low micromolar concentrations (Fig. 2D) . Only 3.7 μM 5-IP 7 was required for 50% inhibition in the single-vesicle docking assay (Fig. 2E) , a value one order of magnitude lower than the IC 50 value measured for the bulk fusion assay (44 μM) (Fig.  2C ). This IC 50 value was approximately one order of magnitude lower than that measured for inhibition of single-vesicle docking by IP 6 , 1-IP 7 , or other IPs (e.g., IP 4 or IP 5 ) (Fig. 2E and Fig. S9 ). Our data imply that the inhibitory effect of 5-IP 7 is more critical for a subset of vesicles with higher fusion activities, because the singlevesicle assay selectively monitors higher-activity vesicles (i.e., those that react within the given 30-s time window). Our observations indicate that 5-IP 7 at tens of micromolar concentrations exhibits a significant inhibitory effect in the presence of 1 mM ATP, which is also a pyrophosphate molecule (41) . Therefore, it appears that the inhibitory effect of 5-IP 7 does not arise from simple electrostatic screening. Instead, 5-IP 7 may regulate one of the components in the minimal vesicle fusion system consisting of lipid molecules, SNAREs, and Syt1 (see below).
The 5-IP 7 Inhibits Synaptic Vesicle Fusion by Targeting Syt1. Next, we examined the molecular target of 5-IP 7 using our in vitro fusion system. First, we removed the SNARE proteins from our fusion assay. Protein-free t vesicles were reacted with v vesicles that were reconstituted with only Syt1. We observed inhibition of vesiclevesicle fusion in a 5-IP 7 -dependent manner (Fig. 3A) . In contrast, removal of Syt1 from the fusion system nearly abolished the inhibitory effect of 5-IP 7 in the concentration range studied (Fig.  3B ). These observations suggest that 5-IP 7 exerts its inhibitory effects on synaptic vesicle fusion by targeting Syt1.
It has been reported that various IPs, including IP 6 , bind to the C2AB domain of Syt1 (16) (17) (18) (19) (20) 45) , which is known to play a crucial role in sensing Ca 2+ ions as well as mediating synaptic membrane fusion (46) . We thus examined binding kinetics of 5-IP 7 and IP 6 to the C2AB domain using surface plasmon resonance (SPR) spectroscopy. To our surprise, the concentration of 5-IP 7 required to obtain a given level of response was 45-fold smaller than that of IP 6 (Fig. 3 C-E) . These SPR data likely indicate that the affinity of 5-IP 7 for Syt1-C2AB binding is enhanced to the same degree, also consistent with the higher efficacy of 5-IP 7 in suppressing in vitro vesicle fusion compared with IP 6 , as shown in Fig. 2 . One more noteworthy observation was that the SPR data showed nearinstantaneous increases and decreases in response units upon addition and removal of 5-IP 7 , IP 6 , and Ca 2+ (Fig. 3 C-E and Fig. S10 ). These observations indicate that binding and unbinding of these small molecules to the Syt1-C2AB domain are fast kinetic processes that cannot be resolved with the time scale of our SPR assay (1 s).
To investigate whether 5-IP 7 acts through Syt1 C2 domains under physiological conditions, we revisited the cell-based noradrenaline release assay shown in Fig. S1 , with the difference that PC12 cells were cotransfected with the IP6K1-WT and GST-tagged Syt1-C2B domain (Fig. S11A) . IP6K1-dependent inhibition of noradrenaline release was significantly rescued by the expression of Syt1-C2B (Fig. S11B) . This result suggests that excess Syt1-C2B domains adsorbed 5-IP 7 , making less 5-IP 7 available for binding to endogenous Syt1, which had the net effect of reactivating the release process. These results collectively indicate that 5-IP 7 suppresses vesicle fusion through interactions with the Syt1-C2AB domain.
Finally, we sought to characterize the molecular interactions of Syt1 with its two ligands, Ca 2+ and 5-IP 7 . We initially performed in vitro vesicle fusion assays under Ca 2+ -chelated conditions. With 5 μM EGTA in the reaction buffer, we observed that 5-IP 7 still exerted a potent, concentration-dependent inhibitory effect on vesicle fusion (Fig. 3F) . This observation indicates that the inhibitory effect of 5-IP 7 does not result from simple inhibition of Ca 2+ binding to Syt1. Instead, 5-IP 7 likely exerts its inhibitory effect through a binding region in C2AB that is independent of the Ca 2+ -binding region. Moreover, our in vitro fusion assay showed that, as the Ca 2+ level was increased in the vesicle fusion assay, the concentration of 5-IP 7 needed to obtain the same level of inhibition concomitantly increased ( Fig. 3 G and H) , suggesting that the inhibitory effect of 5-IP 7 can be overcome by excess Ca 2+ ions.
Discussion
Despite the fundamental importance of IPs in various vesicle trafficking events, there is as yet no consensus on the functional significance of IP 7 in the control of synaptic vesicle exocytosis. To resolve this important issue, we used a combination of cell biology, biochemistry, and single-vesicle biophysical assays. These analyses provide several lines of evidence to show that 5-IP 7 the inhibitory effect of 5-IP 7 results from hindering Ca 2+ binding to Syt1. Conversely, we found that Ca 2+ in excess steered Syt1 toward a fusion-competent conformation. Together, these observations suggest that, although 5-IP 7 and Ca 2+ do not directly compete with each other for Syt1 binding, their relation at the functional level is effectively competitive. In addition, our SPR assays suggest that the binding and unbinding kinetics of Ca 2+ and IP 7 (and IP 6 ) for Syt1 are very rapid. Thus, we hypothesize that Syt1 is in a dynamic equilibrium between fusion-competent and -incompetent conformations, with the balance between them being delicately shifted as Ca 2+ and 5-IP 7 levels are physiologically altered. The functional interaction between 5-IP 7 and Syt1 uncovered in this study suggests a role for 5-IP 7 in controlling the exocytosis process. Intracellular 5-IP 7 concentrations are in the low micromolar range and show extremely rapid and dynamic turnover (9, (22) (23) (24) (25) , consistent with our conclusion that 5-IP 7 functions as a molecular switch for synaptic exocytosis. We speculate that IP6K1 and its product 5-IP 7 may exert multiple modes of regulation at different levels. On one level, 5-IP 7 , the product of IP6K1, can act as a negative regulator of Syt1, thus inhibiting synaptic vesicle fusion. On another level, as previously proposed (21), IP6K1 can directly bind to GRAB in a noncatalytic manner, which facilitates early steps of vesicle docking. Further studies will be needed to elucidate full details of the complex relationship between 5-IP 7 -Syt1 signaling and the IP6K1-GRAB pathway. It would also be interesting to test whether the activity of 5-IP 7 depends on cell typespecific Syt isoforms. Whereas 5-IP 7 functions as a Syt1 inhibitor in neuronal cells, 5-IP 7 may promote insulin exocytosis in the pancreas, where beta cells express the Syt3 isoform, but not Syt1 (27) .
Finally, an imbalance in IP levels in the human body, as well as genetic deletion of IP6K enzymes in mouse models, has been implicated in a number of psychiatric and neurodegenerative diseases (47) (48) (49) (50) . It will be important to gain insights into the structural mechanism underlying high-affinity 5-IP 7 binding and inhibition of the Syt1 protein. We expect that the unique binding of 5-IP 7 to Syt1 can be used to guide the design of small molecules that have therapeutic potential to allosterically control the release of neurotransmitters. 
